| 1.1 Overall survival |
3 |
1521 |
Hazard Ratio (IV, Random, 95% CI) |
0.95 [0.84, 1.07] |
| 1.2 Overall survival by age |
2 |
1220 |
Hazard Ratio (IV, Random, 95% CI) |
0.92 [0.81, 1.05] |
| 1.2.1 Age < 50 years |
1 |
84 |
Hazard Ratio (IV, Random, 95% CI) |
0.91 [0.54, 1.55] |
| 1.2.2 Age <60 years |
1 |
157 |
Hazard Ratio (IV, Random, 95% CI) |
0.71 [0.50, 1.01] |
| 1.2.3 Age 50‐70 years |
1 |
439 |
Hazard Ratio (IV, Random, 95% CI) |
0.96 [0.77, 1.19] |
| 1.2.4 Age 60‐70 years |
1 |
215 |
Hazard Ratio (IV, Random, 95% CI) |
0.95 [0.70, 1.28] |
| 1.2.5 Age > 70 years |
2 |
325 |
Hazard Ratio (IV, Random, 95% CI) |
0.98 [0.77, 1.25] |
| 1.3 Overall survival by residual disease |
1 |
597 |
Hazard Ratio (IV, Random, 95% CI) |
1.09 [0.89, 1.34] |
| 1.3.1 No residual tumour |
1 |
214 |
Hazard Ratio (IV, Random, 95% CI) |
1.17 [0.82, 1.67] |
| 1.3.2 Residual tumour 1‐10 mm |
1 |
161 |
Hazard Ratio (IV, Random, 95% CI) |
1.22 [0.84, 1.77] |
| 1.3.3 Residual tumour > 1 cm |
1 |
222 |
Hazard Ratio (IV, Random, 95% CI) |
0.91 [0.64, 1.30] |
| 1.4 Progression‐free survival |
4 |
1631 |
Hazard Ratio (IV, Random, 95% CI) |
0.97 [0.87, 1.07] |
| 1.5 Severe adverse effects (grade 3+) |
5 |
|
Risk Ratio (IV, Random, 95% CI) |
Subtotals only |
| 1.5.1 Haemorrhage |
2 |
1106 |
Risk Ratio (IV, Random, 95% CI) |
0.99 [0.25, 3.89] |
| 1.5.2 Need for transfusion |
4 |
1085 |
Risk Ratio (IV, Random, 95% CI) |
0.80 [0.65, 0.99] |
| 1.5.3 Venous thromboembolism |
4 |
1490 |
Risk Ratio (IV, Random, 95% CI) |
0.28 [0.09, 0.90] |
| 1.5.4 Infection |
4 |
1490 |
Risk Ratio (IV, Random, 95% CI) |
0.30 [0.16, 0.56] |
| 1.5.5 Gastrointestinal fistula |
4 |
1490 |
Risk Ratio (IV, Random, 95% CI) |
0.39 [0.11, 1.39] |
| 1.5.6 Urinary/vaginal fistula |
2 |
1106 |
Risk Ratio (IV, Random, 95% CI) |
1.06 [0.15, 7.49] |
| 1.5.7 Nausea |
2 |
577 |
Risk Ratio (IV, Random, 95% CI) |
0.42 [0.02, 8.23] |
| 1.5.8 Vomiting |
2 |
577 |
Risk Ratio (IV, Random, 95% CI) |
0.41 [0.03, 6.03] |
| 1.5.9 Diarrhoea |
1 |
474 |
Risk Ratio (IV, Random, 95% CI) |
0.58 [0.11, 3.15] |
| 1.5.10 Neutropenia |
1 |
103 |
Risk Ratio (IV, Random, 95% CI) |
1.15 [0.48, 2.74] |
| 1.5.11 Neutrotoxicity |
1 |
103 |
Risk Ratio (IV, Random, 95% CI) |
1.02 [0.15, 6.97] |
| 1.5.12 Thrombocytopenia |
1 |
103 |
Risk Ratio (IV, Random, 95% CI) |
5.10 [0.25, 103.61] |
| 1.5.13 Febrile neutropenia |
1 |
103 |
Risk Ratio (IV, Random, 95% CI) |
3.06 [0.13, 73.36] |
| 1.5.14 Renal toxicity |
1 |
103 |
Risk Ratio (IV, Random, 95% CI) |
Not estimable |
| 1.5.15 Stoma formation |
2 |
581 |
Risk Ratio (IV, Random, 95% CI) |
0.43 [0.26, 0.72] |
| 1.5.16 Bowel resection |
3 |
1213 |
Risk Ratio (IV, Random, 95% CI) |
0.49 [0.26, 0.92] |
| 1.6 Postoperative mortality |
5 |
1571 |
Risk Ratio (IV, Random, 95% CI) |
0.18 [0.06, 0.54] |
| 1.7 EORTC QLQ‐C30 QoL at 6 months |
2 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.7.1 Global health |
2 |
307 |
Mean Difference (IV, Random, 95% CI) |
‐1.34 [‐2.36, ‐0.32] |
| 1.7.2 Fatigue |
2 |
307 |
Mean Difference (IV, Random, 95% CI) |
‐0.55 [‐6.02, 4.93] |
| 1.7.3 Nausea |
2 |
307 |
Mean Difference (IV, Random, 95% CI) |
2.12 [‐0.36, 4.61] |
| 1.7.4 Pain |
2 |
307 |
Mean Difference (IV, Random, 95% CI) |
0.35 [‐7.41, 8.12] |
| 1.7.5 Constipation |
2 |
307 |
Mean Difference (IV, Random, 95% CI) |
‐2.17 [‐7.24, 2.89] |
| 1.7.6 Insomnia |
2 |
307 |
Mean Difference (IV, Random, 95% CI) |
0.30 [‐0.86, 1.47] |
| 1.7.7 Apetite loss |
2 |
307 |
Mean Difference (IV, Random, 95% CI) |
0.47 [‐0.31, 1.24] |
| 1.7.8 Dyspneoa |
2 |
307 |
Mean Difference (IV, Random, 95% CI) |
2.47 [‐3.42, 8.36] |
| 1.7.9 Diarrhoea |
2 |
307 |
Mean Difference (IV, Random, 95% CI) |
‐0.77 [‐12.69, 11.15] |
| 1.7.10 Financial difficulties |
2 |
307 |
Mean Difference (IV, Random, 95% CI) |
2.46 [‐5.33, 10.25] |
| 1.8 EORTC QLQ‐C30 QoL at 12 months |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8.1 Global health |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8.2 Fatigue |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8.3 Nausea |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8.4 Pain |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8.5 Dyspneoa |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8.6 Insomnia |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8.7 Apetite loss |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8.8 Constipation |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8.9 Diarrhoea |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8.10 Financial difficulties |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.9 Global QoL score |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.9.1 At 6 months |
1 |
217 |
Mean Difference (IV, Random, 95% CI) |
7.60 [1.89, 13.31] |
| 1.9.2 At 12 months |
1 |
133 |
Mean Difference (IV, Random, 95% CI) |
5.70 [‐2.23, 13.63] |
